Iobenguane-I-131

Drug Profile

Iobenguane-I-131

Alternative Names: 131I-iobenguane; 131I-metaiodobenzylguanidine; 131I-MIBG; 3-Iodobenzylguanidine; I-131-MIBG; Iobenguane sulfate; m-Iodobenzylguanidine sulfate

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Jubilant DraxImage
  • Developer Jubilant DraxImage; New Approaches to Neuroblastoma Therapy Consortium
  • Class Antineoplastics; Iodobenzenes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroblastoma

Most Recent Events

  • 09 Jan 2017 Compassionate Use/Expanded access programme by Northwell Health and Cohen Children's Medical Center is temporarily not available for Neuroblastoma (In infants, In children, In adolescents, In adults, Second-line therapy or greater) and Phaeochromocytoma (In infants, In children, In adolescents, In adults, Metastatic disease, Second-line therapy or greater) in USA (NCT03015844)
  • 03 Oct 2016 University of Wisconsin plans a phase I trial for Neuroblastoma (Second-line therapy or greater) in USA, United Kingdom and Germany (NCT02914405)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top